Chris Nolet

Director

Chris Nolet has served as a director and Chair of the Audit Committee at PolarityTE since April 2020. Mr. Nolet has extensive experience in audit with nearly 40 years in the profession. He is a retired audit partner at Ernst & Young where he was most recently the West Region Life Sciences Industry Leader. Prior to EY, Mr. Nolet spent over twenty years at PricewaterhouseCoopers, where he was a partner and led the North America West Life Sciences Industry Group. Mr. Nolet is currently a member of the Board of Directors of three publicly traded biotechnology companies, Viela Bio, Revance Therapeutics and Jasper Therapeutics, Inc. He is also a member of the Executive Committee and is Co-Chair of the Finance Committee of the California Life Sciences Industry Association (CLSA). Mr. Nolet is a former member of the Finance & Investment Committee and Emerging Companies Section of the Biotechnology Innovation Organization, and he has testified before Congress with Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research (CDER), regarding the need for FDA reform. Mr. Nolet holds a B.S. in Accounting from San Diego State University and is a Certified Public Accountant in California.